NEW YORK (GenomeWeb News) – MDxHealth today announced it signed agreements with health insurance providers FedMed and America's Choice Provider Network, extending access to the company's ConfirmMDx prostate cancer test to 50 million additional lives.

FedMed has 40 million covered lives, while ACPN has 11.2 million lives, MDxHealth said. The firm said that more than 130 million covered lives now have access to the ConfirmMDx test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.